TGFβ1 controls PPARγ expression, transcriptional potential, and activity, in part, through Smad3 signaling in murine lung fibroblasts

PPAR Research

Volumn , Issue , 2012, Pages

  Ramirez, Allan ^a   Ballard, Erin N ^a   Roman, Jesse ^a,b  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; LUNG FIBROBLAST; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSGENE;

EID: 84867297840     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/375876     Document Type: Article

References (29)

1. Bonniaud P., Margetts P. J., Ask K., Flanders K., Gauldie J., Kolb M., TGF- β and Smad3 signaling link inflammation to chronic fibrogenesis. Journal of Immunology 2005 175 8 5390 5395 2-s2.0-26844479068 (Pubitemid 41456425)
2. Keane M. P., Belperio J. A., Strieter R. M., Schwarz M. I., King T. E., Cytokine biology and the pathogenesis of interstitial lung disease. Interstitial Lung Disease 2011 5th chapter 16 Shelton, Conn, USA People's Medical Publishing House 365 386
3. Sime P. J., Xing Z., Graham F. L., Csaky K. G., Gauldie J., Adenovector-mediated gene transfer of active transforming growth factor- β 1 induces prolonged severe fibrosis in rat lung. Journal of Clinical Investigation 1997 100 4 768 776 2-s2.0-0030800795 (Pubitemid 27371693)
4. McCormick L. L., Zhang Y., Tootell E., Gilliam A. C., Anti-TGF- β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. Journal of Immunology 1999 163 10 5693 5699 2-s2.0-0033571072
5. Biernacka A., Dobaczewski M., Frangogiannis N. G., TGF- β signaling in fibrosis. Growth Factors 2011 29 196 202 10.3109/08977194.2011.595714
6. Willis B. C., Borok Z., TGF- β -induced EMT: mechanisms and implications for fibrotic lung disease. American Journal of Physiology. Lung Cellular and Molecular Physiology 2007 293 3 L525 L534 2-s2.0-34548411746 10.1152/ajplung.00163.2007 (Pubitemid 47358808)
7. Ramirez A. M., Shen Z., Ritzenthaler J. D., Roman J., Myofibroblast transdifferentiation in obliterative bronchiolitis: TGF- β signaling through Smad3-dependent and -independent pathways. American Journal of Transplantation 2006 6 9 2080 2088 2-s2.0-33746885142 10.1111/j.1600-6143.2006. 01430.x (Pubitemid 44199542)
8. Zhao J., Shi W., Wang Y. L., Chen H., Bringas P., Datto M. B., Frederick J. P., Wang X. F., Warburton D., Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. American Journal of Physiology. Lung Cellular and Molecular Physiology 2002 282 3 L585 L593 2-s2.0-0036086293 (Pubitemid 34654664)
9. Ramirez A. M., Takagawa S., Sekosan M., Jaffe H. A., Varga J., Roman J., Smad3 deficiency ameliorates experimental obliterative bronchiolitis in a heterotopic tracheal transplantation model. American Journal of Pathology 2004 165 4 1223 1232 2-s2.0-4644349675 (Pubitemid 39297728)
10. Giaginis C., Tsourouflis G., Theocharis S., Peroxisome proliferator-activated receptor- γ (PPAR- γ) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. Current Molecular Medicine 2008 8 6 562 579 2-s2.0-53149142762 10.2174/ 156652408785748022
11. Rabinovitch M., PPARg and the pathobiology of pulmonary arterial hypertension. Advances in Experimental Medicine and Biology 2010 661 447 458
12. Kulkarni A. A., Thatcher T. H., Olsen K. C., Maggirwar S. B., Phipps R. P., Sime P. J., PPAR- γ ligands repress TGF β -induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 2011 6 1 2-s2.0-79251563128 10.1371/journal.pone.0015909 e15909
13. Park Y., Freedman B. D., Lee E. J., Park S., Jameson J. L., A dominant negative PPAR γ mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia 2003 46 3 365 377 2-s2.0-0038642086 (Pubitemid 36547592)
14. Blanquicett C., Kang B. Y., Ritzenthaler J. D., Jones D. P., Hart C. M., Oxidative stress modulates PPAR γ in vascular endothelial cells. Free Radical Biology and Medicine 2010 48 12 1618 1625 2-s2.0-77952674282 10.1016/j.freeradbiomed.2010.03.007
15. Kingston R. E., Chen C. A., Rose J. K., Calcium phosphate transfection. Current Protocols in Cell Biology, chapter 9, unit 9. 1, 2003
16. Dyer B. W., Ferrer F. A., Klinedinst D. K., Rodriguez R., A noncommercial dual luciferase enzyme assay system for reporter gene analysis. Analytical Biochemistry 2000 282 1 158 161 2-s2.0-0034660683 10.1006/abio.2000.4605 (Pubitemid 30409441)
17. Standiford T. J., Keshamouni V. C., Reddy R. C., Peroxisome proliferator-activated receptor- γ as a regulator of lung inflammation and repair. Proceedings of the American Thoracic Society 2005 2 3 226 231 2-s2.0-27144456205 10.1513/pats.200501-010AC (Pubitemid 41500850)
18. Sime P. J., The antifibrogenic potential of PPAR γ ligands in pulmonary fibrosis. Journal of Investigative Medicine 2009 56 2 534 538 2-s2.0-70349254621 10.231/JIM.0b013e31816464e9
19. Reddy R. C., Immunomodulatory role of PPAR- γ in alveolar macrophages. Journal of Investigative Medicine 2009 56 2 522 527 2-s2.0-70349239310 10.231/JIM.0b013e3181659972
20. Becker J., Delayre-Orthez C., Frossard N., Pons F., Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundamental and Clinical Pharmacology 2006 20 5 429 447 2-s2.0-33748701308 10.1111/j.1472-8206.2006.00425.x (Pubitemid 44393958)
21. Wei J., Ghosh A. K., Sargent J. L., Komura K., Wu M., Huang Q. Q., Jain M., Whitfield M. L., Feghali-Bostwick C., Varga J., PPAR γ downregulation by tgf in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010 5 11 2-s2.0-78349281192 10.1371/journal.pone.0013778 e13778
22. Fu M., Zhang J., Lin Y., Zhu X., Zhao L., Ahmad M., Ehrengruber M. U., Chen Y. E., Early stimulation and late inhibition of peroxisome proliferator-activated receptor γ (PPAR γ) gene expression by transformino growth factor β in human aortic smooth muscle cells: role of early growth-response factor-1 (Egr-1), activator protein 1 (AP1) and Smads. Biochemical Journal 2003 370 3 1019 1025 2-s2.0-0037444798 10.1042/BJ20021503 (Pubitemid 36399096)
23. Lin L. C., Hsu S. L., Wu C. L., Liu W. C., Hsueh C. M., Peroxisome proliferator-activated receptor γ (PPAR γ) plays a critical role in the development of TGF β resistance of H460 cell. Cellular Signalling 2011 23 10 1640 1650 2-s2.0-79960706214 10.1016/j.cellsig.2011.05.018
24. Terai K., Call M. K., Saika S., Liu C. Y., Hayashi Y., Chikama T., Zhang J., Terai N., Kao C. W., Kao W. W., Crosstalk between TGFb and MAPK signaling during corneal wound healing. Investigative Ophthalmology & Visual Science 2011 52 8208 8215
25. Zheng S., Chen A., Disruption of transforming growth factor- β signaling by curcumin induces gene expression of peroxisome proliferator- activated receptor- γ in rat hepatic stellate cells. American Journal of Physiology. Gastrointestinal and Liver Physiology 2007 292 1 G113 G123 2-s2.0-33846146367 10.1152/ajpgi.00200.2006 (Pubitemid 46090257)
26. Choy L., Derynck R., Transforming growth factor- β inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. Journal of Biological Chemistry 2003 278 11 9609 9619 2-s2.0-0038322020 10.1074/jbc.M212259200 (Pubitemid 36800456)
27. Santibaez J. F. S., Quintanilla M., Bernabeu C., TGF- β /TGF- β receptor system and its role in physiological and pathological conditions. Clinical Science 2011 121 6 233 251 2-s2.0-79961139550 10.1042/CS20110086
28. Yki-Jarvinen H., Thiazolidinediones. The New England Journal of Medicine 2004 351 1106 1118
29. Scheen A. J., Thiazolidinediones and liver toxicity. Diabetes and Metabolism 2001 27 3 305 313 2-s2.0-0034930107 (Pubitemid 32625383)